Cynata Therapeutics Limited(ASX: CYP) is a clinical-stage stem cell and regenerative medicine company. Cynata is focussed on the development and commercialisation of a proprietaryinduced pluripotent stem cell (iPSC)-based platform technology,Cymerus™. Mesenchymal stem cells(also known asmesenchymal st...
Cynata’s CYP-004 MSC product is the subject of a Phase 3 clinical trial being sponsored by the University of Sydney and funded by an Australian Government National Health and Medical Research Council (NHMRC) competitive Project Grant in addition to in-kind contributions from participating institutio...
Cynata Therapeutics的目标价为每股A$0.75,由Euroz Hartleys提供支持>CYP.AU Cynata Therapeutics的起始股价为0.75澳元/股,目标价为Euroz Hartleys>CYP。 道琼斯11/06 11:00 Cynata Therapeutics Ltd:向股东提交的年度报告 澳洲交易所10/18 10:44· 业绩公告 Cynata Therapeutics Ltd:附录 4E 和年度报告 08/29 16:...
Cynata Therapeutics的pegy比率于kesäkuu 2021触及5年低点,是-11.65。 Cynata Therapeutics的pegy比率于2020 (-0.55, -197.1%)、2021 (-11.65, +2,034.2%)和2024 (-0.09, -822.1%)减少和于2022 (-0.27, -97.7%)和2023 (0.01, -104.7%)增加。 相比竞争对手,Cynata Therapeutics Ltd的PEGY比率基准如何? 我...
Cynata Therapeutics LtdASX:CYP1.00 HealthcareSECTOR:HLTH.AU1.00 Chimeric Therapeutics LtdASX:CHM1.00 Adalta LtdASX:1AD1.00 Orthocell LtdASX:OCC1.00 Vectus Biosystems LtdASX:VBS1.00 Neuroscientific Biopharmaceuticals LtdASX:NSB1.00 BCAL Diagnostics LtdASX:BDX1.00 ...
View Cynata Therapeutics Ltd (CYPOA) stock price, news, historical charts, analyst ratings, financial information and quotes on Futubull. Trade commission-free with the Futubull stock trading app.
Cynata Therapeutics的平均ev/ebit(10年)是-10.4x. 查看Cynata Therapeutics Ltd的平均EV/EBIT(10年)趋势、图表等
Cynata Therapeutics的ev/最近12个月ebitda减资本支出于มิถุนายน 2020触及5年低点,是-11.7x。 Cynata Therapeutics的ev/最近12个月ebitda减资本支出于2020 (-11.7x, -28.3%)、2021 (-7.4x, -36.5%)、2022 (-5.4x, -27.7%)和2023 (-0.5x, -90.8%)增加。